Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Hexarelin peptide icon, one bubble per amino acidHexarelin6 residues (approx.)HWAWFKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Hexarelin

Beginner tier: 100 mcg, daily · community consensus

70 min half-life·Injection

Also known as: Examorelin, HEX, EP-23905

Six amino acids double the growth hormone release of GHRH at the same IV dose [1]. GHRP-2 matched that pulse at equal doses [3]. Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic growth hormone releasing peptide that hits both the pituitary GHS-R1a receptor and a separate cardiac CD36 receptor. Other GHRPs share that dual action profile [12]. It reached Phase II clinical trials for GH deficiency and congestive heart failure in the 1990s before development stopped. The tradeoff is real: hexarelin raises cortisol and prolactin, about as much as GHRP-2 does at equal doses [3]. Receptor desensitization limits continuous use to roughly four weeks. Experienced users run it in short, intense cycles stacked with a GHRH for maximum output.

What Is Hexarelin?

Growth hormone release about twice that of GHRH at the same IV dose. Ghigo and colleagues measured this in 12 healthy young volunteers, with a dose-dependent response after subcutaneous injection too [1]. GHRP-2 matched hexarelin's GH pulse at equal IV doses in two head-to-head studies [3][9]. Hexarelin is a synthetic hexapeptide GHS-R1a agonist, sometimes listed under CAS 140703-51-1, that mimics ghrelin at both the pituitary and hypothalamus to trigger growth hormone release.

Hexarelin also binds a second target, the CD36 scavenger receptor. Bodart and colleagues found this second binding site in rat heart tissue in 1999 [2] and identified it as CD36 in 2002 [7]. Through CD36, hexarelin produces anti-fibrotic cardiac effects and preserves cell contractility during ischemia, completely independent of the GH axis. Other GHRPs share this dual profile. A 2017 review describes the GHRP family as binding both GHS-R1a and CD36 [12].

The practical reality is a 4-week ceiling. Hexarelin's high GHS-R1a binding affinity drives receptor downregulation faster than any other peptide in this class. Community protocols converge on 4 weeks on, 2 to 4 weeks off, with many users adding 5-on/2-off weekly cycling within each block to slow desensitization further. The typical stack pairs 100 to 200 mcg hexarelin with 100 mcg CJC-1295 (no DAC) co-injected subcutaneously at bedtime.

About 311 PubMed papers cover hexarelin. Most are mechanistic or short-term pharmacological work, not long-term therapeutic trials. It reached Phase II for adult GH deficiency and heart failure before development was abandoned, likely because desensitization made chronic dosing impractical. It was never submitted for FDA approval and remains a research-only compound. Community experience across dozens of Reddit threads tracks closely with the published pharmacology; the 100 to 200 mcg per injection dosing range is where most users land.

How Hexarelin Works

Hexarelin binds GHS-R1a at the anterior pituitary with higher affinity than any other growth hormone releasing peptide. That binding triggers a calcium-dependent signaling cascade in somatotroph cells, producing a GH pulse within 30 minutes of subcutaneous injection. Unlike ipamorelin, which is selective for GHS-R1a, hexarelin also activates ACTH release from the pituitary. This cross-reactivity explains the cortisol and prolactin elevations that Arvat and colleagues measured in healthy adults [3]. GHRP-2 at matched doses raised them by similar amounts in the same study.

The second receptor is what sets hexarelin apart. Bodart's group identified CD36, a scavenger receptor expressed on cardiomyocytes, as a direct hexarelin binding target [7]. Through CD36, hexarelin reduces cardiac fibrosis, preserves cell shortening during ischemia-reperfusion injury, and regulates intracellular calcium handling. A 2018 mouse study confirmed that hexarelin treatment preserves myocardial function and reduces fibrosis after acute myocardial infarction [4]. These cardiac effects operate entirely independently of GH release.

Plasma half-life runs approximately 55 to 70 minutes after subcutaneous injection, with GH peak occurring around 30 minutes post-dose. Oral bioavailability is only about 0.3%, making subcutaneous injection the only practical route. The short half-life means each injection produces a discrete GH pulse rather than sustained elevation; that pulsatile pattern mimics natural physiology better than continuous GH administration.

Hexarelin Benefits

  • Hexarelin benefits center on short-cycle GH output and a cardiac mechanism through the CD36 receptor.
  • Releases about twice the GH of GHRH at the same IV dose [1], and the response nears its ceiling at 1 to 2 mcg/kg IV [5]. GHRP-2 matched it head to head at equal IV doses [3][9].
  • Binds the CD36 cardiac receptor independently of GH release. Mouse models show preserved myocardial function and reduced fibrosis after acute infarction [4]. Other GHRPs bind CD36 too, per a 2017 review of the peptide family [12].
  • Sleep architecture improves with bedtime dosing. GH promotes slow-wave sleep, and community reports consistently flag deeper sleep as one of the first noticeable effects within the opening 2 to 3 doses.
  • Complementary with GHRH peptides through dual receptor activation. Pairing hexarelin (GHS-R1a) with CJC-1295 no DAC (GHRHR) produces a GH pulse larger than either compound alone.
  • Body recomposition signal within a 4-week window. Users report reduced abdominal fat and improved muscle fullness by weeks 3 to 4, particularly at the intermediate 200 mcg twice daily protocol.
  • Recovery from training accelerates during on-cycle weeks. Community consensus places noticeable recovery improvement at the 1 to 2 week mark, consistent with the IGF-1 elevation timeline from sustained GH pulsing.

Hexarelin: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 18 key studies·Research only

Potent GHS-R1a agonist in human dose-response trials: about twice the GH release of GHRH at 1 mcg/kg IV [1].

Dosing studied: Phase I/II research SC: 1.5–3 mcg/kg per injection. Clinical trial ceiling effect at ~2 mcg/kg IV (~140 mcg/70 kg subject). No therapeutic SC RCT exists for the community 100-300 mcg range.
Read the evidence (key study, limitations)

Reached Phase II clinical trials for adult GH deficiency and congestive heart failure (1990s); development discontinued, likely due to desensitization limiting long-term utility. Never FDA-approved. Rat heart studies found a distinct cardiac hexarelin receptor [2], later identified as CD36 [7]. Hexarelin protected rat hearts from ischemia/reperfusion injury, partly through GHS-R1a and, one group concluded, largely through CD36 [6][8], not validated in human clinical endpoints. GH, prolactin, ACTH and cortisol rises matched GHRP-2 at equal IV doses in two small human studies [3][9]. Head-to-head human data against GHRP-6 or ipamorelin are lacking. ~311 PubMed papers; the majority are mechanistic or short-term pharmacological studies, not therapeutic RCTs.

Key Study

Ghigo et al. 1994 (PMID 8126144): dose-response and route comparison in healthy men; established SC efficacy and dose ceiling. Bodart et al. 1999 (PMID 10532947): found a new 84 kDa cardiac hexarelin receptor that MK-0677 does not bind; Bodart et al. 2002 (PMID 11988484) identified it as CD36. Arvat et al. 1997 (PMID 9285939): in 6 healthy young adults, hexarelin and GHRP-2 at equal IV doses raised prolactin, ACTH and cortisol by similar amounts.

Limitations

No long-term therapeutic RCT for SC dosing. Desensitization mechanism documented in animals; formal human desensitization kinetics unpublished. Oral bioavailability ~0.3% (clinical trial data): not a practical route. SC bioavailability not formally quantified in humans (estimated 60-70% from mechanistic extrapolation). All cardioprotective data from animal models or in vitro: no human clinical endpoints confirmed.

Community Experience
Moderate
3.5/5
Based on dozens of r/Peptides and r/steroids threads

Highly respected but niche and considered an advanced GHRP.

Community dosing: 100–200 mcg per injection SC, once or twice daily fasted
Read the reports (what users report 5, common issues 5)

Strong consensus on it producing the largest GH pulse of any GHRP ("nothing else touches it for raw GH output") but most experienced users ultimately migrate to ipamorelin for long-term use due to cleaner hormonal profile and no desensitization. Hexarelin is reserved for short, intense cycles where maximum GH output is the priority. CD36 cardioprotective mechanism is frequently cited as a differentiator.

What users report (5)
  • Community reports call it the strongest raw GH pulse of any GHRP
  • Cardioprotective CD36 mechanism: a frequently cited differentiator
  • Pronounced sleep quality improvement with bedtime dosing
  • Rapid body recomposition signal in short 4-week cycles
  • Synergistic with GHRH for amplified GH pulse vs. either alone
Common issues (5)
  • Receptor desensitization: fastest of any GHRP; 4-week cap limits sustained use
  • Community reports rank its cortisol and prolactin rises above ipamorelin and GHRP-2
  • Community often reports "hexarelin stopped working": almost always due to exceeding 4-week continuous use
  • More side effects than ipamorelin drives users to cleaner alternatives for long-term protocols
  • Strict fasting window required: blunting from food is significant
Partially Aligned

Science and community agree on GHS-R1a mechanism, a strong GH pulse, cortisol/prolactin elevation, and the principle of receptor desensitization requiring cycling. Community has independently converged on 4-week on/off cycling and the CJC-1295 no DAC stack: both mechanistically justified. Community SC dosing (100-300 mcg) extrapolates beyond any published clinical therapeutic RCT; 300 mcg 2×/day exceeds clinical dose-response ceiling. Science and community split on ranking. Community reports put hexarelin's GH pulse and its cortisol and prolactin rises above GHRP-2's. Two human studies at equal IV doses found all of them similar (PMID 9285939, 10195374). Community reports also treat CD36 as hexarelin's edge over other GHRPs; a 2017 review places CD36 binding across the GHRP family (PMID 28469491).

Hexarelin Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner100 mcg
DailyTrack
Moderate200 mcg
2x DailyTrack
Aggressive300 mcg
2x DailyTrack
Note:

Stack hexarelin with a GHRH, not another GHRP. The single most common mistake is pairing it with ipamorelin or GHRP-2. Both hit the same GHS-R1a receptor. You're wasting one compound. The correct partner is CJC-1295 (no DAC) or sermorelin, co-injected simultaneously.

Reconstitution math for a 5mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg/mL. On a U-100 insulin syringe, 4 units equals 100 mcg, 8 units equals 200 mcg, 12 units equals 300 mcg. For a 2mg vial with 2 mL BAC water, you get 1,000 mcg/mL; 10 units equals 100 mcg.

Fasting compliance matters more with hexarelin than most peptides. Carbohydrates and fats raise somatostatin, which blunts the GH pulse considerably. No food 30 minutes before or after injection at minimum. Two hours post-meal is better. If your IGF-1 isn't moving after 4 weeks, check your fasting window before blaming the product.

Refrigerate reconstituted vials and use within 3 to 4 weeks.

Cycling Protocol

On Period
4 weeks
Off Period
4 weeks

Hexarelin desensitizes GHS receptors with continuous use. Cycle 4 weeks on, 2-4 weeks off to maintain GH responsiveness. Some protocols use 5 days on, 2 days off within each on-cycle week.

Calculate your Hexarelin dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Hexarelin Protocols by Goal

beginnerCommunity4 weeks on, 4 weeks off
Ramp-in
Wk 1-2
100 mcg · Once daily (bedtime) · Subcutaneous
Maintenance
Wk 3-4
100 mcg · Once daily (bedtime), 5 days on / 2 days off each week · Subcutaneous

Expected: Sleep quality improvement within weeks 1-2; recovery improvement by weeks 2-3; modest body composition changes (reduced abdominal fat, improved muscle fullness) by end of 4-week cycle

Monitor: Baseline IGF-1 before starting; recheck at week 4. Fasting glucose at baseline.

How to Inject Hexarelin

  1. 1
    Reconstitute the vial

    For a 5mg vial, slowly inject 2 mL bacteriostatic water down the inside wall of the vial. Do not shake. Swirl gently until the powder dissolves completely. This gives you 2,500 mcg per mL.

  2. 2
    Step 2

    Draw your dose using a U-100 insulin syringe (29-31 gauge, 0.5 inch needle). For 100 mcg, draw to the 4-unit mark. For 200 mcg, draw to 8 units. For 300 mcg, draw to 12 units.

  3. 3
    Step 3

    Choose your injection site: abdomen (2 inches from the navel) or the fatty tissue on the outer thigh. Rotate sites with each injection.

  4. 4
    Clean the injection site with an alcohol swab

    Pinch a fold of skin, insert the needle at a 45-degree angle, inject slowly, hold for 5 seconds, then withdraw.

  5. 5
    Timing matters

    Best timing is 30 to 60 minutes before bed to amplify the natural nocturnal GH pulse. For twice-daily protocols, the morning dose should be on waking and fully fasted. Keep a minimum of 3 to 4 hours between injections.

  6. 6
    Step 6

    If stacking with CJC-1295 (no DAC), draw both peptides into the same syringe and co-inject simultaneously. Do not pre-mix vials.

  7. 7
    Step 7

    Store the reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 3 to 4 weeks. Never freeze reconstituted solution.

Mixing your own vial? Use the Hexarelin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Hexarelin Stacking Protocols

Works With

Avoid

Ipamorelin

Both hexarelin and ipamorelin bind the same GHS-R1a receptor. Co-administration provides no additive GH benefit and accelerates receptor desensitization. Choose one GHRP and stack it with a GHRH peptide instead: the most common hexarelin mistake per community consensus.

Do not combine
GHRP-2

Same GHS-R1a receptor. Hexarelin already has the highest binding affinity of any GHRP. At equal doses, it and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939). Combining them compounds these side effects with no additional GH benefit from dual GHS-R1a occupancy.

Do not combine
GHRP-6

Same GHS-R1a receptor. Stacking hexarelin + GHRP-6 is redundant. GHRP-6 adds intense hunger stimulation and cortisol burden with no additive GH benefit over hexarelin alone.

Do not combine
Exogenous HGH (recombinant GH / somatropin)

Combining GH secretagogues with exogenous recombinant HGH saturates the GH/IGF-1 axis and suppresses endogenous pulsatility. Eliminates the primary rationale for secretagogue use. Dramatically increases IGF-1 overshoot risk.

Do not combine

Estimated Cost

Brand Price
No FDA-approved or branded pharmaceutical hexarelin product exists for human use. Never reached commercial approval.
Generic / Research
2mg vial: $14-35 USD (range; ~$7-18/mg). 5mg vial: $45-76 USD (~$9-15/mg). At 200 mcg/day (moderate, once daily), a 5mg vial lasts 25 days: approximately $1.80-$3.00/day.
Compounded
No US compounding route is listed: Hexarelin is not on the 503A bulk drug substances list, and FDA has not placed it in any 503A category (list updated May 14, 2026) or 503B category (list updated March 21, 2025).

Pricing updated 2026-04-09

Hexarelin Side Effects

Cortisol and prolactin elevation are the primary safety concerns with hexarelin. Community reports often rank it the worst GHRP for both. The human head-to-head tests against GHRP-2 don't back that ranking. Arvat's group gave both at equal IV doses in two small studies, and prolactin, ACTH and cortisol rose by similar amounts [3][9]. At the beginner 100 mcg once daily dose, the cortisol bump is transient and typically returns to baseline within 2 to 3 hours post-injection. Rahim's group tracked cortisol in adults through 16 weeks of 1.5 mcg/kg twice daily, about 105 mcg at 70 kg [10]. The cortisol response to the morning injection was lower at week 16 than at baseline, and it recovered 4 weeks after stopping. The ACTH response, basal cortisol and 24-hour urinary free cortisol did not change. A one-day study in 6 young men found two or three injections left 24-hour cortisol, ACTH and prolactin output unchanged [11]. The aggressive 300 mcg twice daily protocol runs about three times Rahim's dose and lacks long-term data. Community reports at that dose describe disrupted sleep, irritability and shifts in fat distribution, which users blame on cortisol.

Prolactin follows a similar dose-dependent pattern. At lower doses, the spike is brief and unlikely to produce symptoms. Over Rahim's 16 weeks of twice-daily dosing, the prolactin response did not change [10]. At higher twice-daily doses, community reports describe libido changes and, rarely, early gynecomastia signs. Checking prolactin at baseline and at week 4 is standard practice for anyone running intermediate or advanced protocols. Some users add low-dose cabergoline during aggressive cycles, though clinical backing for that approach in this context is thin.

GHS-R1a receptor desensitization is not a side effect in the traditional sense, but it is the most common reason hexarelin "stops working." High-affinity binding drives beta-arrestin-mediated receptor internalization faster than GHRP-2, GHRP-6, or ipamorelin. The community figured this out before any formal study characterized the kinetics in humans. Four weeks of continuous daily dosing is the practical limit; beyond that, GH pulse magnitude drops noticeably. Receptor density recovers over 2 to 4 weeks off.

Water retention and mild edema are common GH-class effects. At higher doses, fluid accumulation in the carpal tunnel can produce hand tingling, numbness, or grip weakness. These are early carpal tunnel symptoms. If they persist beyond a few days at a reduced dose, stopping the cycle entirely and allowing 4 or more weeks for resolution is the right call.

Appetite increase occurs through the ghrelin pathway. It's less intense than GHRP-6, but still present, especially at 200 mcg and above. This can actually disrupt the fasting window required for proper dosing if not managed. Shifting the bedtime dose to 3 or more hours after dinner helps.

Post-injection flushing and tingling within 10 to 20 minutes is a GH flush effect and is harmless. It's actually a useful signal: when the flush stops appearing in later weeks, it often indicates desensitization has begun.

Hexarelin has not been studied in pregnant or breastfeeding individuals. GH and IGF-1 elevation carry theoretical risks for fetal development and should be avoided entirely. Anyone with active malignancy, pituitary tumors, intracranial hypertension, or uncontrolled diabetes should not use hexarelin. GH elevation impairs glucose tolerance and may promote tumor growth through the IGF-1 axis.

When to see a doctor: persistent carpal tunnel symptoms beyond one week, fasting glucose climbing above 125 mg/dL, any signs of prolactin elevation (libido changes, breast tissue changes), or edema that doesn't resolve with dose reduction.

Common Issues & Solutions

No IGF-1 movement after 4-6 weeks: Most common cause is eating within 30-60 min before/after injection: carbohydrates and fats raise somatostatin and blunt the GH pulse significantly. Verify fasting compliance before questioning product quality or dosing.

GH response decreasing week over week ("hexarelin stopped working"): Classic GHS-R1a desensitization. Implement 5-on/2-off weekly schedule immediately; if already past 4 weeks continuous, stop for at least 2 weeks minimum (4 preferred) before resuming. Receptor sensitivity typically restores within 2-4 weeks off.

Hand tingling, numbness, or grip weakness: Early carpal tunnel symptoms from GH-mediated fluid retention in the carpal tunnel. Reduce dose or injection frequency immediately. If symptoms persist beyond 1 week at lower dose, discontinue and allow 4+ weeks for GH-related edema to resolve.

Sleep disrupted despite bedtime dosing or cortisol-like symptoms (fat gain, irritability): Hexarelin raises ACTH and cortisol about as much as GHRP-2 does at equal doses [3]. At aggressive doses (300 mcg 2×/day) this is clinically relevant. Check AM cortisol; consider dose reduction or switching to ipamorelin for subsequent cycles.

Post-injection intense hunger: Less than GHRP-6 but still present: particularly at higher doses. This is a ghrelin-pathway side effect. If hunger disrupts fasting compliance, shift bedtime dose later (post-dinner, 3+ hours fasted) or consider switching to ipamorelin for cleaner dosing.

Ask AI about this page

Ask AI for a second opinion on Hexarelin dosing and side effects

Contraindications

  • Active malignancy or history of cancer (GH and IGF-1 elevation may promote tumor growth)
  • Pregnancy or breastfeeding (insufficient safety data in humans)
  • Severe cardiac arrhythmias (requires cardiac monitoring despite cardioprotective research)
  • Uncontrolled diabetes or significant insulin resistance (GH elevation impairs glucose tolerance)
  • Known hypersensitivity to hexarelin or related GH secretagogue peptides
  • Active pituitary tumors or intracranial hypertension

Drug Interactions

  • Exogenous growth hormone (HGH): concurrent use risks supraphysiological GH levels and amplified side effects
  • Glucocorticoids (prednisone, dexamethasone): may blunt GH release and reduce hexarelin efficacy
  • Insulin: combined GH elevation can worsen glucose tolerance; monitor blood sugar closely
  • Somatostatin analogs (octreotide): directly oppose GH release and will negate hexarelin effects
  • Testosterone and estrogen compounds: may potentiate GH-releasing effects of hexarelin, requiring dose adjustment
  • Both hexarelin and ipamorelin bind the same GHS-R1a receptor. Co-administration provides no additive GH benefit and accelerates receptor desensitization. Choose one GHRP and stack it with a GHRH peptide instead: the most common hexarelin mistake per community consensus.
  • Same GHS-R1a receptor. Hexarelin already has the highest binding affinity of any GHRP. At equal doses, it and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939). Combining them compounds these side effects with no additional GH benefit from dual GHS-R1a occupancy.
  • Same GHS-R1a receptor. Stacking hexarelin + GHRP-6 is redundant. GHRP-6 adds intense hunger stimulation and cortisol burden with no additive GH benefit over hexarelin alone.

Product Quality

Recommended Monitoring

TestWhenTarget
IGF-1Baseline before starting; repeat at week 4 (end of on-cycle)Age-adjusted normal range: not supraphysiological. Flag if above upper limit of normal.
Fasting glucoseBaseline; repeat at week 4; weekly if pre-diabetic<100 mg/dL (normal); 100-125 mg/dL warrants dose reduction and closer monitoring
ProlactinBaseline; repeat at week 4 if libido changes or gynecomastia signs emergeNormal laboratory reference range for sex
AM cortisolBaseline; repeat at week 4 if cortisol symptoms emerge (disrupted sleep, fat gain, irritability)Normal AM cortisol range (approximately 6-23 mcg/dL at 8 AM)
Thyroid (TSH, fT3, fT4)Baseline; repeat at week 12 of ongoing protocols if symptoms emergeNot listed
IGF-1

Primary efficacy marker for sustained GH axis activation. Confirms product quality and dosing adequacy. Detects over-response requiring dose reduction. IGF-1 responds to consistent pulsing within 2-4 weeks.

Fasting glucose

GH release antagonizes insulin action. Hexarelin-induced cortisol co-elevation further impairs glucose tolerance at higher doses. Essential in any individual with insulin resistance history.

Prolactin

Hexarelin raises prolactin about as much as GHRP-2 does at equal doses (PMID 9285939). Returns to baseline within 2-3h post-injection. In adults given 16 weeks of twice-daily injections, the prolactin response did not change (PMID 10341859). Relevant especially at intermediate/advanced doses.

AM cortisol

Hexarelin raises ACTH and cortisol; two human studies found rises similar to GHRP-2 at equal doses (PMID 9285939, 10195374). In adults on 1.5 mcg/kg twice daily for 16 weeks, the cortisol response fell and recovered after stopping (PMID 10341859). Their 24-hour urinary free cortisol did not change. The 300 mcg twice daily protocol lacks long-term data.

Thyroid (TSH, fT3, fT4)

GH accelerates T4-to-T3 conversion. Untreated hypothyroidism blunts GH response; GH axis activation can unmask subclinical hypothyroidism.

Hexarelin Before and After

Days 1-3

Initial GH pulse detectable within 30 minutes of first dose. Mild hunger increase and possible facial flushing. Sleep quality may begin to improve with evening dosing.

Week 1

Consistent GH and IGF-1 elevation. Noticeable appetite increase. Mild water retention and potential tingling or numbness at higher doses.

Weeks 2-3

Recovery benefits become apparent. Fat loss and improved sleep solidify. Cortisol and prolactin effects may be noticeable at aggressive doses.

Week 4

Peak GH response before receptor desensitization sets in. Best body composition changes observed. Transition to off-cycle period recommended.

Weeks 5-8
off-cycle

GHS receptor sensitivity resets over 2-4 weeks. Most body composition gains are retained. GH and IGF-1 gradually return toward baseline.

What to Expect

Days 1 to 3, Initial GH pulse. The GH spike hits within 30 minutes of your first subcutaneous injection, per pharmacokinetic data from Ghigo's 1994 study [1]. Most users notice a warmth and tingling sensation 10 to 20 minutes post-injection. That's the GH flush. Sleep quality often starts improving within the first 2 to 3 doses if you're dosing at bedtime. Mild appetite increase kicks in through the ghrelin pathway. Some users report facial flushing at higher starting doses. Cortisol and prolactin both elevate transiently but return to baseline within 2 to 3 hours.

Weeks 1 to 2, GH and IGF-1 climbing. Consistent GH pulsing with each injection drives IGF-1 upward, measurable on bloodwork by week 2 to 4. Sleep quality improvement solidifies. Recovery between training sessions gets noticeably faster. Mild water retention is common. The appetite bump post-injection is manageable at beginner doses but more pronounced at 200 mcg twice daily. Tingling in extremities may appear at higher doses from GH-mediated fluid retention.

Weeks 2 to 3, peak response window. This is where body composition changes start showing. GH-mediated lipolysis and IGF-1 anabolic signaling have been accumulating for two weeks. Reduced abdominal fat and improved muscle fullness become visible. Recovery from training is well established. If you're running continuous daily dosing without 5-on/2-off weekly breaks, the GH response per injection may already be diminishing. Cortisol and prolactin effects become more noticeable at the 300 mcg aggressive dose level.

Week 4, desensitization threshold. Best body composition results of the cycle are typically visible at this point. The post-injection flush and tingling that was strong in weeks 1 to 2 starts fading. That's not tolerance in the casual sense; it's GHS-R1a receptor downregulation from high-affinity binding. The community strongly recommends transitioning to the off-cycle here. Extending beyond 4 weeks produces diminishing returns with the same side effect burden.

Weeks 5 to 8, off-cycle recovery. Hexarelin clears plasma within hours of the last injection (half-life roughly 70 minutes). GHS-R1a receptor density recovers over 2 to 4 weeks off. The good news: body composition gains from the 4-week cycle are largely retained for 4 to 6 weeks post-cycle. Sleep quality may dip modestly compared to on-cycle. Appetite returns to baseline within days. Water retention resolves. IGF-1 gradually returns toward pre-cycle levels. Most users plan their next cycle after a full 4-week off period.

Detailed Timeline: Science vs Community

Days 1-3
Science

GH pulse detectable within 30 min of SC injection per PK data (PMID 8126144). GH promotes slow-wave sleep architecture. Cortisol and prolactin transient elevation returns to baseline within 2-3h post-injection.

Community

Post-injection warmth and tingling within 10-20 min is common (GH flush effect). Sleep improvement often noticed within first 2-3 doses. Mild appetite increase. Some users report facial flushing at higher doses.

Weeks 1-2
Science

Consistent GH pulsing with each injection. IGF-1 begins rising, measurable by week 2-4. GH stimulates slow-wave sleep. Cortisol and prolactin elevation remains transient per injection (PMID 9285939).

Community

Consistent sleep quality improvement with bedtime dosing. Recovery from training noticeably faster. Mild water retention. Appetite increase manageable. Users at 200 mcg 2×/day begin noticing recovery gains.

Weeks 2-3
Science

GH-mediated lipolysis and IGF-1 anabolic signaling accumulate. GHS-R1a desensitization beginning to develop with continuous daily use without 5-on/2-off cycling.

Community

Body composition improvements become visible: reduced abdominal fat, improved muscle fullness. Recovery solidified. Users on continuous protocols (no weekly breaks) start noticing diminishing post-injection response. Cortisol/prolactin effects more noticeable at 300 mcg aggressive doses.

Week 4
Science

GHS-R1a receptor downregulation progresses with continuous use; peak GH pulse per injection declining. Best timepoint to transition to off-cycle to allow receptor recovery.

Community

Best body composition changes of the cycle visible at week 4. Post-injection flush/tingling diminishing (sign of receptor desensitization). Community strongly recommends not extending beyond this point.

Weeks 5-8 (off-cycle)
Science

Short plasma half-life (~70 min) means compound clears within hours of last injection. GHS-R1a receptor density recovers over 2-4 weeks off.

Community

Body composition gains (lean mass, reduced fat) largely retained for 4-6 weeks post-cycle. Sleep quality may decline modestly vs. on-cycle. Most users plan next cycle after 4 weeks off. IGF-1 returns toward baseline.

Pharmacokinetics

Half-Life
1.17h
Bioavailability
SC: estimated 60-70%; Oral: ~0.3%
Tmax
~0.5 hours (GH peak at ~30 min)
Data Confidence
moderate

Source: Human plasma t½ ~55-70 min (Ghigo et al. 1994, PMID 8126144; rat IV t½ 75.9 min, PMID 10611139)

Pharmacokinetics: Active Dose Over Time

t½ = ~70 min

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
6
Molecular Weight
887.04 Da
Sequence
HWAWFK
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 140703-51-1

Who Should Consider Hexarelin

  • Adults seeking a strong GH pulse for short-term body recomposition cycles
  • Individuals interested in peptide-based cardioprotective support (research context)
  • Experienced peptide users comfortable managing cortisol and prolactin elevation
  • Athletes in short recovery-focused phases who can cycle on and off appropriately
  • Researchers studying GHS-R1a and CD36-mediated cardiac signaling pathways

Related Peptides

What Changed for Hexarelin

  1. Safety

    Corrected Oct 17, 2026: the hexarelin cortisol study gives no ages in its abstract, so these pages say adults, not older adults, per Rahim 1999.

    Before: In healthy older adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859) After: In adults on hexarelin, 16 weeks of twice-daily injections lowered the cortisol response (PMID 10341859)

    What this does not mean: The finding stands: 16 weeks of twice-daily hexarelin lowered the cortisol response and left the prolactin response unchanged. Only the description of the study group changed.

    Also covers: GHRP-2, GHRP-6

    Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  2. Safety

    Corrected Oct 16, 2026: in older adults, 16 weeks of twice-daily hexarelin lowered the cortisol response, not the prolactin response, per Rahim 1999.

    Before: At 300 mcg twice daily the cumulative cortisol burden becomes clinically meaningful; at higher twice-daily doses prolactin can rise enough to affect libido After: In older adults on 1.5 mcg/kg twice daily for 16 weeks the cortisol response fell and the prolactin response did not change (PMID 10341859); higher-dose symptoms labelled community reports

    What this does not mean: Hexarelin still raises cortisol, ACTH and prolactin after each injection. The 300 mcg twice daily protocol lacks long-term data, and community reports of poor sleep at that dose stay on the page.

    Source: Clin Endocrinol 1999, The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  3. Safety

    Corrected Oct 16, 2026: hexarelin raises prolactin, ACTH and cortisol by about as much as GHRP-2 at equal doses, not more, per Arvat 1997.

    Before: Cortisol and prolactin rises more pronounced than with any other GHRP; Popovic's group confirmed this against GHRP-2 at equivalent doses (PMID 9285939) After: Community reports rank hexarelin worst for both; in Arvat's two small studies, prolactin, ACTH and cortisol rose by similar amounts with hexarelin and GHRP-2 at equal IV doses (PMID 9285939, 10195374)

    What this does not mean: Hexarelin still raises prolactin, ACTH and cortisol. The page had credited this paper to Popovic 1995. Human head-to-head data against GHRP-6 or ipamorelin on these hormones are lacking.

    Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

  4. Safety

    Corrected Oct 16, 2026: the hexarelin + GHRP-2 warning no longer says hexarelin has the highest cortisol and prolactin rise of any GHRP, per Arvat 1997.

    Before: Hexarelin already has the highest binding affinity and cortisol/prolactin elevation of any GHRP After: Hexarelin already has the highest binding affinity of any GHRP; at equal doses it and GHRP-2 raise cortisol and prolactin by similar amounts (PMID 9285939)

    What this does not mean: Stacking hexarelin with GHRP-2 is still advised against. Both bind GHS-R1a, add no GH benefit together, and raise cortisol and prolactin.

    Source: Peptides 1997, Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man (Arvat et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 7, 202618 Citations

References

  1. [1]Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after various routes of administration in man (J Clin Endocrinol Metab 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Identification and characterization of a new growth hormone-releasing peptide receptor in the heart (Circ Res 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH and cortisol levels in man (Arvat et al., Peptides 1997) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction (Am J Transl Res 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]Growth hormone-releasing activity of hexarelin in humans: a dose-response study (Eur J Clin Pharmacol 1995) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]The growth hormone secretagogue hexarelin protects rat cardiomyocytes from in vivo ischemia/reperfusion injury through interleukin-1 signaling pathway (Huang et al., Int Heart J 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart (Bodart et al., Circ Res 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
  8. [8]Ghrelin plays a minor role in the physiological control of cardiac function in the rat (Torsello et al., Endocrinology 2003) (opens in a new tab)PubMed (opens in a new tab)PubMed
  9. [9]Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans (Arvat et al., J Endocrinol Invest 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  10. [10]The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin (Rahim et al., Clin Endocrinol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  11. [11]Impact of two or three daily subcutaneous injections of hexarelin on 24-h GH, prolactin, ACTH and cortisol secretion in humans (Maccario et al., Eur J Endocrinol 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
  12. [12]Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects (Berlanga-Acosta et al., Clin Med Insights Cardiol 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
  13. [13]GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats (Deghenghi et al., Life Sci 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C, stable up to 12 months
After Reconstitution
Refrigerate, use within 3-4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Hexarelin binds GHS-R1a with higher affinity than GHRP-2, GHRP-6, or ipamorelin, and that means more receptor downregulation with continuous use. Desensitization typically sets in after 4-6 weeks of daily dosing, noticeably reducing your GH pulse. A 2-4 week off period lets receptor density recover.

No, this is one of the most common mistakes. Both compete for the same GHS-R1a receptor. Taking both doesn't amplify anything; it wastes one compound. The correct stack is hexarelin (or any single GHRP) with a GHRH like Mod GRF 1-29 or sermorelin, different receptor pathways that actually synergize.

At beginner doses (100 mcg/day), it's mild and usually not clinically significant. At aggressive doses (300 mcg 2x/day), community reports describe poorer sleep and stalled fat loss, though that dose lacks long-term data. In a 16-week trial in adults at 1.5 mcg/kg twice daily, the cortisol response fell and the prolactin response did not change (PMID 10341859). Some users add vitamin C, ashwagandha, or low-dose cabergoline during cycles, though that adds complexity without strong clinical backing.

It reached Phase II trials for GH deficiency and congestive heart failure in the 1990s. Development stopped. Not because of safety failures, but likely because the desensitization issue limited long-term use, and the competitive market moved on. Never submitted for FDA approval.

Hexarelin binds the CD36 scavenger receptor on heart cells independently of GH release, producing anti-fibrotic effects and preserved contractility during ischemia. These effects show up in animal models at doses that extrapolate to the 100-200 mcg human range. Whether that benefit translates to healthy individuals (rather than ischemic models) is unknown.